Lead Product(s) : Desidustat
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Indian Council of Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus and ICMR Start Phase 2 Desidustat Trial in Sickle Cell Disease
Details : Rytstat (desidustat), first-of-its-kind oral tablet being investigated for the treatment for Sickle Cell Disease, in India.
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2024
Lead Product(s) : Desidustat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Indian Council of Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxemia (desidustat), a HIF-PF inhibitor met its primary endpoints for haemoglobin improvement in DREAM-D and DREAM-ND Phase III clinical trials and showed good safety profile, downregulation of hepcidin, improved iron mobilization and LDL-C reduction in ...
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Seeks DCGI Approval for Novel Oral Pill to Treat Anaemia in Kidney Patients
Details : The study demonstrated the noninferiority of Desidustat compared to Epoetin in the treatment of anemia in patients with CKD who were on dialysis. Desidustat is also under clinical trials for Cancer Chemotherapy Induced Anemia (CIA).
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desidustat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2(b) results of this study revealed that Desidustat treatment led to increased red blood cell production and improved oxygen delivery to tissues.
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Desidustat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Zydus inks pact with China Medical System to market Desidustat in Greater China
Details : Under the terms and conditions of the agreement, CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.
Product Name : Oxemia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 20, 2020
Lead Product(s) : Desidustat
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : China Medical System Holdings Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement